ReviewNature reviews. Disease primers2018
Hypertension.
Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 607 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
607 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,087 citations in OpenAlex.
- Psychological determinants of medication adherence in patients with hypertension: a systematic review and meta‑analysis.Journal of behavioral medicine · 2026Pooled it
- Exploring the benefits and safety of combining nebivolol and valsartan for managing hypertension: a systematic review.BMC cardiovascular disorders · 2026Pooled it
- Associations Between Polygenic Risk Score for Blood Pressure and Risk of Hypertension in Northeast Asian Individuals.Journal of the American Heart Association · 2026Pooled it
- Can resistance training alone or resistance training combined with aerobic training improve arterial stiffness, endothelial function, and other vascular function indicators in adults with hypertension or overweight/obesity-related vascular risk? A systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2026Pooled it
- Arterial spin labeling MRI in assessing cerebral blood flow changes due to hypertension: a systematic review.Journal of hypertension · 2026Pooled it
- Effects of dynamic resistance training on blood pressure across different baseline levels: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Targeting a systolic blood pressure of <130 mmHg is beneficial in adults with hypertension aged ≥75 years: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: A meta-analysis.Journal of internal medicine · 2025Pooled it
- An RCT META analysis based on the efficacy of Tai Chi exercise therapy on blood pressure and blood lipids in patients with essential hypertension.Frontiers in cardiovascular medicine · 2025Pooled it
- Exploring the research progression and evolutionary trends of gut microbiome and hypertension: a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.Journal of the American Heart Association · 2026Trial
- Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- Increased fluid intake and blood pressure in healthy children: a randomized controlled trial. The SPA Project.Pediatric nephrology (Berlin, Germany) · 2026Trial
- Trial
- No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration-QTc Modeling Assessment.Pharmacology research & perspectives · 2025Trial
- Direct carotid sinus nerve stimulation in anesthetized human subjects.Scientific reports · 2025Trial
- A Smartphone-Guided Digital Health Application for Hypertension: The Randomized Controlled HELP Trial.Deutsches Arzteblatt international · 2025Trial
- Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension.Cardiovascular drugs and therapy · 2024Trial
- Unveiling the impact of colonic pH and pH-sensing receptors in blood pressure regulation.Gut microbes · 2026Review
547 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 6 countries.
Funding
Abstract
Systemic arterial hypertension is the most important modifiable risk factor for all-cause morbidity and mortality worldwide and is associated with an increased risk of cardiovascular disease (CVD). Fewer than half of those with hypertension are aware of their condition, and many others are aware but not treated or inadequately treated, although successful treatment of hypertension reduces the global burden of disease and mortality. The aetiology of hypertension involves the complex interplay of environmental and pathophysiological factors that affect multiple systems, as well as genetic predisposition. The evaluation of patients with hypertension includes accurate standardized blood pressure (BP) measurement, assessment of the patients' predicted risk of atherosclerotic CVD and evidence of target-organ damage, and detection of secondary causes of hypertension and presence of comorbidities (such as CVD and kidney disease). Lifestyle changes, including dietary modifications and increased physical activity, are effective in lowering BP and preventing hypertension and its CVD sequelae. Pharmacological therapy is very effective in lowering BP and in preventing CVD outcomes in most patients; first-line antihypertensive medications include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, dihydropyridine calcium-channel blockers and thiazide diuretics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.